# Cancer Genetics (CG)

> **NIH NIH P30** · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2024 · $77,090

## Abstract

PROJECT SUMMARY/ABSTRACT (CANCER GENETICS)
The University of Michigan (U-M) Rogel Cancer Center (Rogel) Cancer Genetics (CG) Program is a group of
interdisciplinary researchers who seek to advance knowledge of the genetic and epigenetic mechanisms that
underlie cancer development and progression. Investigators in the CG Program perform basic and translational
research aimed at understanding the origins and nature of cancer, thereby leading to novel preventive and
diagnostic approaches as well as the improved clinical management of cancer patients. To reach these goals,
the CG Program is organized as a diverse, interdisciplinary research group with 42 members from 18
departments within four U-M schools/colleges (i.e., Medical School; School of Public Health, School of
Kinesiology, College of Literature, Science and the Arts). Currently, annual direct research support totals $11.6M
in cancer grant funding with $3.2M (28%) from NCI, $3.6M (31%) from other NIH grants, and $2.1M (18%) from
additional peer-reviewed funding. CG members are actively involved in intra- and inter-programmatic interactions
with researchers in the Basic Science, Clinical Research, and Cancer Control and Population Sciences
Programs. The work being done by CG members is particularly relevant to five of the Rogel’s cross-cutting
research themes, specifically i) molecular determinants of cancer; ii) biomarkers; iii) genetics and gene
environment, iv) targets and therapeutics and v) inflammation, microbes, and immunity. With combined effort,
the Program has generated important insights in cancer development, diagnosis, treatment, and prevention,
having authored a total of almost 700 cancer-relevant publications during the project period, of which 18.7% were
intra-programmatic and 46% were inter-programmatic. In the current proposal, three scientific aims are detailed:
1) Elucidate the genetic and epigenetic mechanisms of cancer development and progression, 2) Utilize novel
animal model systems for characterizing the impact of critical genetic alterations found in human cancers, and
3) Generate new knowledge for translation into effective strategies for prevention, early diagnosis, and treatment.
By focusing efforts on shared scientific interest across Rogel programs, in tandem with a commitment to training
as well as mentorship, CG Program members have generated a cohesive body of knowledge that has yielded
novel and important insights into the genetic and epigenetic mechanisms underlying cancer initiation and
progression. In keeping with these accomplishments, the Program seeks to further advance the development
of new strategies for preventing, diagnosing, and treating cancer.

## Key facts

- **NIH application ID:** 10875448
- **Project number:** 5P30CA046592-35
- **Recipient organization:** UNIVERSITY OF MICHIGAN AT ANN ARBOR
- **Principal Investigator:** KATHLEEN R. CHO
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $77,090
- **Award type:** 5
- **Project period:** 1997-06-01 → 2028-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10875448

## Citation

> US National Institutes of Health, RePORTER application 10875448, Cancer Genetics (CG) (5P30CA046592-35). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10875448. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*